Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma

BACKGROUND: Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T) therapy showed remarkable efficacy in patients with relapsed or refractory multiple myeloma (RRMM). This phase 1 dose-escalation and expansion study developed C-CAR088, a novel second-generation humanized anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Xiaoyan, An, Gang, Sui, Weiwei, Wang, Tingyu, Zhang, Xian, Yang, Junfang, Zhang, Yan, Zhang, Lu, Zhu, Dan, Huang, Jiaqi, Zhu, Shigui, Yao, Xin, Li, Jing, Zheng, Chengxiao, Zhu, Kevin, Wei, Yutian, Lv, Xiaoteng, Lan, Liping, Yao, Yihong, Zhou, Daobin, Lu, Peihua, Qiu, Lugui, Li, Jianyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472147/
https://www.ncbi.nlm.nih.gov/pubmed/36100310
http://dx.doi.org/10.1136/jitc-2022-005145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472147/
https://www.ncbi.nlm.nih.gov/pubmed/36100310
http://dx.doi.org/10.1136/jitc-2022-005145

Ejemplares similares